AU2021101743A4 - Preparation Method of Polygonatum sibiricum Tea Bag Combined with Exercise for Prevention and Adjuvant Therapy for Hyperglycemia - Google Patents
Preparation Method of Polygonatum sibiricum Tea Bag Combined with Exercise for Prevention and Adjuvant Therapy for Hyperglycemia Download PDFInfo
- Publication number
- AU2021101743A4 AU2021101743A4 AU2021101743A AU2021101743A AU2021101743A4 AU 2021101743 A4 AU2021101743 A4 AU 2021101743A4 AU 2021101743 A AU2021101743 A AU 2021101743A AU 2021101743 A AU2021101743 A AU 2021101743A AU 2021101743 A4 AU2021101743 A4 AU 2021101743A4
- Authority
- AU
- Australia
- Prior art keywords
- parts
- polygonatum sibiricum
- hyperglycemia
- tea bag
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000037831 Polygonatum sibiricum Species 0.000 title claims abstract description 44
- 201000001421 hyperglycemia Diseases 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 230000002265 prevention Effects 0.000 title claims abstract description 21
- 238000009098 adjuvant therapy Methods 0.000 title claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 68
- 244000248557 Ophiopogon japonicus Species 0.000 claims abstract description 22
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 20
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 20
- 244000183278 Nephelium litchi Species 0.000 claims abstract description 19
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 18
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 18
- 241000519406 Paphiopedilum Species 0.000 claims abstract description 16
- 235000008434 ginseng Nutrition 0.000 claims abstract description 16
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 claims abstract description 15
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 14
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 14
- 240000004638 Dendrobium nobile Species 0.000 claims abstract description 11
- 240000004371 Panax ginseng Species 0.000 claims abstract description 11
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 11
- 235000015742 Nephelium litchi Nutrition 0.000 claims abstract description 10
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims abstract description 8
- 244000269722 Thea sinensis Species 0.000 claims abstract 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 239000012141 concentrate Substances 0.000 claims description 17
- 238000010992 reflux Methods 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 235000008216 herbs Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 240000004307 Citrus medica Species 0.000 claims description 8
- 235000001938 Citrus medica Nutrition 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000002203 pretreatment Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 31
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 24
- 229940079593 drug Drugs 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 241001122767 Theaceae Species 0.000 description 21
- 239000008103 glucose Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000013641 positive control Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- 230000002218 hypoglycaemic effect Effects 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 244000179970 Monarda didyma Species 0.000 description 10
- 235000010672 Monarda didyma Nutrition 0.000 description 10
- 230000000291 postprandial effect Effects 0.000 description 9
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 8
- 229960002632 acarbose Drugs 0.000 description 8
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 241000180649 Panax notoginseng Species 0.000 description 7
- 235000003143 Panax notoginseng Nutrition 0.000 description 7
- 244000131316 Panax pseudoginseng Species 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 241000748223 Alisma Species 0.000 description 6
- 235000002791 Panax Nutrition 0.000 description 6
- 241000208343 Panax Species 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 241001523681 Dendrobium Species 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 208000031971 Yin Deficiency Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- 241001126925 Lobata Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 241000219780 Pueraria Species 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 3
- 241000756943 Codonopsis Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- 102000004366 Glucosidases Human genes 0.000 description 3
- 108010056771 Glucosidases Proteins 0.000 description 3
- 241000745390 Lophatherum Species 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 244000025361 Ficus carica Species 0.000 description 2
- 235000008730 Ficus carica Nutrition 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- 244000273256 Phragmites communis Species 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 244000274050 Platycodon grandiflorum Species 0.000 description 2
- 241000405911 Rehmannia glutinosa Species 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000017924 poor diet Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000009877 shengmai Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 150000003675 ursolic acids Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/22—Drying or concentrating tea extract
- A23F3/225—Drying or concentrating tea extract by evaporation, e.g. drying in thin layers, foam drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
The invention discloses a preparation method of Polygonatum sibiricum tea bag combined
with exercise for prevention and adjuvant therapy for hyperglycemia. The Polygonatum
sibiricum tea bag comprises the following components in parts by mass: prepared Polygonatum
sibiricum 25-35 parts, Ophiopogon japonicus 10-20 parts, Dendrobium nobile 10-20 parts,
Codonopsis pilosula 10-20 parts, Citrus medica sarcodactylis 20-40 parts, Litchi chinensis
seeds 10-20 parts, Ganoderma lucidum spore powder 10-20 parts, lophatherum gracile 10-20
parts, Alisma orientale 10-20 parts, Panax ginseng 10-20 parts, Pueraria lobata 25-35 parts,
25-35 parts of Grey Paphiopedilum; According to the changes of modem living habits and
environment, combined with the dialectical treatment of hyperglycemia in traditional Chinese
medicine, the present invention selects some traditional Chinese medicine with the same source
of medicine and food for compatibility, and prepares bag tea to prevent and assist the treatment
of hyperglycemia. The tea bag is convenient to take, taking into account the symptoms of
diabetes and various syndromes, can enhance the curative effect of other drugs, from the
essence of conditioning, and green safety, can be long-term substitute tea drink.
1/1
FIGURES
0.500
0.450
0.433
0.400 07
0.350 0.353
330
0.300
0.250
0.200 y =0.019x+0.209
R= 0.986
0.150
0.100
0.050
0.000
0 2 4 6 8 10 12 14
Figure 1
Description
1/1
0.500 0.450 0.433 0.400 07 0.350 0.353 330 0.300 0.250 0.200 y =0.019x+0.209 R= 0.986 0.150
0.100
0.050
0.000 0 2 4 6 8 10 12 14
Figure 1
Preparation Method of Polygonatum sibiricum Tea Bag Combined with Exercise for
Prevention and Adjuvant Therapy for Hyperglycemia
The invention belongs to the field of traditional Chinese medicine preparations, and
in particular relates to a preparation method of Polygonatum sibiricum tea bag combined
with exercise for prevention and adjuvant therapy for hyperglycemia.
With the continuous preparement of economy and society, the changes of people's life
rhythm, law and diet structure lead to hyperglycemia becoming a common disease
endangering human health. In recent years, the range of patients has expanded rapidly and
has far-reaching influence. Especially, people are more worried about the growing youth
of patients. Hyperglycemia has become the third "health killer" of human beings. The
prevalence rate of diabetes among adults over 20 years old in China is 9.7%, and China has
become the country with the largest number of diabetes patients. Nowadays, the main ways
to treat diabetes are to improve the life style of patients and take western medicine
hypoglycemic drugs, such as insulin and its analogues. Although this treatment can
alleviate the patient's symptoms to a certain extent, it needs to rely on drugs for a long time,
and the side effects of taking drugs for a long time and causing great damage to the body.
Hyperglycemia in traditional Chinese medicine is basically consistent with diabetes
in modern medicine. Traditional Chinese medicine dialectically believes that the main
causes of hyperglycemia are poor diet, emotional disorder, excessive labor desire,
insufficient innate endowment and excessive taking of warm and dry drugs or food.
According to different syndrome types, it can be divided into lung heat and fluid injury
type, stomach heat excess type, kidney yin deficiency type and yin and yang deficiency
type. Treatment principle is dialectical treatment according to different syndrome types.
There are many traditional Chinese medicines used to treat hyperglycemia, such as
Ophiopogon japonicus, Trichosanthes kirilowii, Rehmannia glutinosa, Phragmites
australisand Puerarialobata.
Teabag refers to tea which is packed into bags after tea leaves, coarse powder of cut
pieces or partial coarse powder of cut pieces are dried, among which tea bags for drinking
are also called teabags. The processing technology of teabag is relatively simple, and it is
convenient to store, transport and take, which accords with the usage habits of modern
people. In addition, because of its low price, it is easily accepted by patients as an auxiliary
treatment.
At present, the activity evaluation of traditional Chinese medicine in the treatment of
diabetes mainly adopts the animal model of diabetes and the inhibition experiment of a
glucosidase in vitro. For example, Huang Tianming et al. (Huang Tianming. Synthesis of
Ursolic Acid Derivatives and Study on Their a-Glucosidase Inhibition Activity [D].
Guangdong University of Technology, 2015.) verified the inhibitory effect of Ursolic Acid
Derivatives on a-Glucosidase activity in vitro. Wu Zhe et al. (Wu Zhe. Study on
hypoglycemic effect and hypoglycemic components of three kinds of plant mixtures [D].
Shanxi University, 2015.) verified the hypoglycemic effect of three kinds of plant mixtures
with diabetic animal model; Yu Ting (Yu Ting. Effect of fermentation on the main
components of Platycodon grandiflorum and its hypoglycemic effect [D]. Yanbian
University, 2015.), etc. verified the effect of fermentation on the hypoglycemic active components of Platycodon grandiflorumby using diabetic animal models; Huang Dandan et al. (Huang Dandan. Study on Extraction and Hypoglycemic Effect of Total Flavonoids from Ficus carica Leaves [D]. Fujian Medical University, 2015.) verified the hypoglycemic effect of Total Flavonoids from Ficus carica Leaves combined with a -glucosidase inhibition experiment in vitro and animal model of diabetes.
Hyperglycemia is diabetes. At present, the treatment of diabetes mainly adopts oral
hypoglycemic western medicine and insulin injection. Oral drugs mainly include insulin
secretagogues, insulin sensitizers, biguanides and so on. However, taking hypoglycemic
western medicine for a long time has certain influence on liver and kidney function, and
has great side effects. Therefore, it is safer, greener and more effective to use Chinese
medicine as auxiliary treatment to correct the deviation of the body and restore the body to
a healthy balance state. At present, there are many traditional Chinese medicines for
treating hyperglycemia, such as Ophiopogon japonicus, Trichosanthes kirilowii,
Rehmannia glutinosa, Phragmites australis and Puerarialobata. Common prescriptions
include Shengmai Powder, Qiwei Baizhu Powder, Dihuang Yinzi, Yuquan Pill and so on.
However, these drugs and prescriptions often only aim at a certain factor in the formation
of hyperglycemia, and only aim at a single symptom in hyperglycemia.
In view of this, the present invention aims at the above problems to provide a
preparation method of Polygonatum sibiricum tea bag combined with exercise for
prevention and adjuvant therapy for hyperglycemia. Accord to that change of living habit
and environment of modern people, combined with the dialectical treatment of
hyperglycemia by traditional Chinese medicine, some traditional Chinese medicines with the same medicine and food are selected for compatibility, and the teabag is prepared to prevent and assist in the treatment of hyperglycemia. The tea bag is convenient to take, takes into account the symptoms of diabetes and various syndromes produced, can enhance the curative effects of other drugs, is conditioned in essence, is green and safe, and can replace tea for a long time. This tea bag can provide help for the treatment of hyperglycemia.
To solve the above technical problems, the invention provides a preparation method
of Polygonatum sibiricum tea bag combined with exercise for prevention and adjuvant
therapy for hyperglycemia, and it comprises the following components in parts by mass:
prepared Polygonatum sibiricum 25-35 parts, Ophiopogon japonicus 10-20 parts,
Dendrobium nobile 10-20 parts, Codonopsis pilosula 10-20 parts, Citrus medica
sarcodactylis 20-40 parts, Litchi chinensis seeds 10-20 parts, Ganoderma lucidum spore
powder 10-20 parts, lophatherumgracile 10-20 parts, Alisma orientale 10-20 parts, Panax
ginseng 10-20 parts, Puerarialobata 25-35 parts, 25-35 parts of Grey Paphiopedilum;
The preparation method of Polygonatum sibiricum tea bag combined with exercise
for prevention and adjuvant therapy for hyperglycemia comprises the following steps:
Step 1: Pre-treatment of raw materials: Weigh the Litchi chinensis seeds, Codonopsis
pilosula, Pueraria lobata, Polygonatum sibiricum, Grey Paphiopedilum, lophatherum
gracile, Alisma orientale, Ophiopogonjaponicus,Citrus medica sarcodactylisand Panax
ginseng and dry them; crush all the herbs, which are passed through a sieve and take the
coarse powder.
Step 2: Weighing: Weighing the pre-treated coarse powder according to the mass
parts: prepared Polygonatum sibiricum 25-35 parts, Ophiopogonjaponicus 10-20 parts,
Dendrobium nobile 10-20 parts, Codonopsis pilosula 10-20 parts, Citrus medica
sarcodactylis 20-40 parts, Litchi chinensis seeds 10-20 parts, Ganoderma lucidum spore
powder 10-20 parts, lophatherumgracile 10-20 parts, Alisma orientale 10-20 parts, Panax
ginseng 10-20 parts, Puerarialobata 25-35 parts, 25-35 parts of Grey Paphiopedilum.
Step 3: Prepare the concentrated liquid.
Step 4: Mix the weighed Citrus medica sarcodactylis, Panaxginseng coarse powder
and Ganoderma lucidum spore powder with the concentrated liquid prepared in Step 3,
stirring it continuously to make it uniform; dry it in a constant temperature oven, take out
the dried product, crush it into coarse powder, bag it, and obtain the Polygonatum sibiricum
tea bag for prevention and adjuvant therapy for hyperglycemia.
Further, the coarse powder in step 1 can pass through a 24 mesh sieve, and the mass
of the powder passing through a 65 mesh sieve does not exceed 40% of the total coarse
powder mass.
Furthermore, the drying temperature in step 1 is 50°C-60°C.
Further, the concentrate solution prepareed in that step 3 specifically comprises the
following steps:
Step 3.1: Mix the weighed LLitchi chinensis seeds, Codonopsis pilosula, Pueraria
lobata, Polygonatum sibiricum, Grey Paphiopedilum, lophatherum gracile, Alisma
orientale, Ophiopogonjaponicus,Citrus medica sarcodactylis and Panaxginseng, add 60
degrees-65 degrees edible alcohol according to the weight ratio of 1:6-1:8; heat reflux for
0.5h-1.5h, take the filtrate, concentrate; cool and store in 4°C refrigerator, set aside; then
combine the two aqueous extracts in step 3.1, heat reflux for 30-60min each time; then
combine the two aqueous extracts, concentrate the volume with that of step 2.
Step 3.2: Take the dregs from step 3.1, add 8 times the amount of water, heat and
reflux twice, 30-60min each time; then combine the two water extracts, heat and
concentrate, the volume after concentration is the same as in step 2; cool and store in a
refrigerator at 4°C, and set aside.
Step 3.3. Take the concentrated solution prepareed in step 3.1 and step 3.2 and mix,
then concentrate, and the volume after concentration is one third of that in step 2; prepare
the concentrated solution and set aside
In addition, the drying temperature in step 4 is 50°C-60°C; Drying time is 8h-10h.
Compared with the prior art, the present invention can obtain technical effects
including the following.
1) The extraction scheme is designed differently for the effective parts of different
herbs, and the bagged tea is then prepareed after extraction, which greatly improves the
effect.
2) The herbs with co-existing fat-soluble and water-soluble components are designed
with an alcohol extraction followed by water extraction scheme to give full play to the
medicinal effect.
(3) Water-soluble ingredients of precious fine herbs into the drug using the original
powder, while as an excipient to avoid adding other excipients, making the product more
pure.
(4) The invention takes into account several essential factors for the formation of high
blood sugar in the formula, which makes the application more extensive. It also takes into
account the characteristics of modem people's life, and achieves comprehensive regulation
and improvement in terms of activating blood stasis, tonifying the liver and kidney, strengthening the spleen and benefiting the qi, and tranquilizing the mind. And the selected herbs are non-toxic natural herbs, mostly medicinal and food herbs, which are safer and can be taken for a long time.
Certainly, the implementation of any product of the present invention does not
necessarily need to achieve all the technical effects described above at the same time.
The drawings described here are used to provide a further understanding of the present
invention and constitute a part of the present invention. The illustrative embodiments of
the present invention and their descriptions are used to explain the present invention, and
do not constitute an improper limitation of the present invention. In the drawings:
Fig. 1 is a standard curve of the product of the present invention.
The embodiments of the present invention will be described in detail with examples
below, so as to fully understand and implement the realization process of how to apply
technical means to solve technical problems and achieve technical efficiency.
The invention provides a preparation method of Polygonatum sibiricum tea bag
combined with exercise for prevention and adjuvant therapy for hyperglycemia, and it
comprises the following components in parts by mass: prepared Polygonatum sibiricum
-35 parts, Ophiopogon japonicus 10-20 parts, Dendrobium nobile 10-20 parts,
Codonopsispilosula 10-20 parts, Citrus medica sarcodactylis20-40 parts, Litchi chinensis
seeds 10-20 parts, Ganodermalucidum spore powder 10-20 parts, lophatherumgracile 10
parts, Alisma orientale 10-20 parts, Panax ginseng 10-20 parts, Puerarialobata 25-35
parts, 25-35 parts of Grey Paphiopedilum;
The preparation method of Polygonatum sibiricum tea bag combined with exercise
for prevention and adjuvant therapy for hyperglycemia comprises the following steps:
Step 1: Pre-treatment of raw materials: Weigh the Litchi chinensis seeds, Codonopsis
pilosula, Pueraria lobata, Polygonatum sibiricum, Grey Paphiopedilum, lophatherum
gracile, Alisma orientale, Ophiopogonjaponicus,Citrus medica sarcodactylisand Panax
ginseng, remobe the impurities, and dry them; crush all the herbs, which are passed through
a sieve and take the coarse powder (The coarse powder can pass through 24 mesh sieve,
and the mass of the powder passing through 65 mesh sieve does not exceed 40% of the
total coarse powder mass).
Step 2: Weighing: Weighing the pre-treated coarse powder according to the mass
parts: prepared Polygonatum sibiricum 25-35 parts, Ophiopogonjaponicus 10-20 parts,
Dendrobium nobile 10-20 parts, Codonopsis pilosula 10-20 parts, Citrus medica
sarcodactylis 20-40 parts, Litchi chinensis seeds 10-20 parts, Ganoderma lucidum spore
powder 10-20 parts, lophatherumgracile 10-20 parts, Alisma orientale 10-20 parts, Panax
ginseng 10-20 parts, Puerarialobata 25-35 parts, 25-35 parts of Grey Paphiopedilum.
Step 3: Prepare the concentrated liquid.
Step 3.1: Mix the weighed LLitchi chinensis seeds, Codonopsis pilosula, Pueraria
lobata, Polygonatum sibiricum, Grey Paphiopedilum, lophatherum gracile, Alisma
orientale, Ophiopogonjaponicus,Citrus medica sarcodactylis and Panaxginseng, add 60
degrees-65 degrees edible alcohol according to the weight ratio of 1:6-1:8; heat reflux for
0.5h-1.5h, take the filtrate, concentrate; cool and store in 4°C refrigerator, set aside; then
combine the two aqueous extracts in step 3.1, heat reflux for 30-60min each time; then
combine the two aqueous extracts, concentrate the volume with that of step 2.
Step 3.2: Take the dregs from step 3.1, add 8 times the amount of water, heat and
reflux twice, 30-60min each time; then combine the two water extracts, heat and
concentrate, the volume after concentration is the same as in step 2; cool and store in a
refrigerator at 4°C, and set aside.
Step 3.3. Take the concentrated solution prepareed in step 3.1 and step 3.2 and mix,
then concentrate, and the volume after concentration is one third of that in step 2; prepare
the concentrated solution and set aside; At this time, the concentrated solution is easy to
hang on the wall, very viscous and easy to conjunctiva on the surface
Step 4: Mix the weighed Citrus medica sarcodactylis, Panaxginseng coarse powder
and Ganoderma lucidum spore powder with the concentrated liquid prepared in Step 3,
stirring it continuously to make it uniform; while the drying temperature in step 4 is 50°C
°C; Drying time is 8h-10h.dry it in a constant temperature oven, take out the dried
product, crush it into coarse powder, bag it, and obtain the final product.
Further, the coarse powder in step 1 can pass through a 24 mesh sieve, and the mass
of the powder passing through a 65 mesh sieve does not exceed 40% of the total coarse
powder mass.
Hyperglycemia is a disease characterized by polydipsia, polyphagia, polyuria, fatigue,
emaciation or sweet urine. According to the clinical characteristics of hyperglycemia, it
mainly refers to diabetes in western medicine. Its etiology is complex, lack of endowment,
poor diet, emotional disorder, excessive labor desire and other reasons can lead to thirst
quenching. Pathogenesis mainly lies in deficiency of yin and Jin and excessive dryness and
heat. Yin deficiency is the basis, dryness and heat are the standard, and they are mutually
causal. The more yin is deficient, the more dry and hot it is, the more yin is deficient. The diseased viscera are mainly in lung, stomach and kidney, especially kidney. Among the three dirty things, although each has its own emphasis, they often influence each other.
Treatment is based on yin deficiency and dryness-heat, with nourishing yin, clearing heat
and moistening dryness as the main method, and the pure medicine is to nourish yin with
sweetness and cold, but the effect is not satisfactory. In recent years, it has been found that
the drugs of regulating qi, promoting blood circulation and dispelling wind can always
achieve better curative effect in clinical treatment. Analysis of its mechanism may be: the
pathogenesis of hyperglycemia exists in the stagnation of triple energizer's intestines and
stomach, and the imbalance of gas-liquid metabolism, which leads to the complicated
situation of dryness and dampness coexisting. Therefore, the treatment can't be cold and
moist alone, and the method of opening Xuanfu with wind medicine Xinrun has become
another way to treat hyperglycemia. Secondly, wind drugs are mostly pungent and warm,
and wind drugs are used in the treatment of hyperglycemia and its symptoms to promote
yang and disperse body fluid; Open Xuanfu to promote qi circulation, promote blood
circulation and dredge collaterals. In the prescription, Huang Jing nourishes yin and
moistens the lungs, and is good at tonifying spleen and nourishing qi, lung, spleen and
kidney, and qi and yin; The bergamot can soothe the liver, regulate qi, and eliminate
phlegm. Ophiopogonjaponicusand Dendrobium nobile nourish yin and moisten the lungs,
benefit the stomach and promote fluid production, clear the heart and remove annoyance;
Litchi seeds promote qi circulation and dissipate stagnation, while Codonopsis pilosula
strengthens spleen and benefits qi, which can help monarch drugs nourish yin and moisten
dryness, soothe liver and regulate qi. Ganoderma lucidum spore powder tranquilizes the
mind; Panaxpseudo-ginsengpromotes blood circulation; Puerarialobata dispels wind and evil, promotes yang and disperses body fluid; Lophatherum gracile andAlisma orientalis are all adjuvant drugs. The above compatibility not only cuts to the pathogenesis of hyperglycemia and yin deficiency and dryness-heat, but also makes the dryness-heat and blood stasis of triple energizer get rid of, and qi-fluid is transported to cloth, which can treat both the symptoms and root causes.
Example 1
A preparation method of Polygonatum sibiricum teabag combined with exercise
prevention and auxiliary treatment of hyperglycemia comprises the following components
in parts by mass: prepared Polygonatum sibiricum 30 parts, Ophiopogonjaponicus 15
parts, Dendrobium nobile 15 parts, Codonopsispilosula15 parts, bergamot 30 parts, litchi
seeds 15 parts, Ganoderma lucidum spore powder 15 parts, lophatherum gracile 15 parts,
Alisma orientalis 15 parts, Panax notoginseng 15 parts, Puerarialobata 30 parts and Grey
Paphiopedilum30 parts.
The Polygonatum sibiricum tea bag for preventing and adjuvant treating
hyperglycemia is prepared by the following method:
Step 1: According to the above formula, take litchi seeds, Dendrobium, Codonopsis
pilosula, Puerarialobata, Polygonatum sibiricum, Grey Paphiopedilum, Lophatherum
gracile, Alisma orientaleand Ophiopogonjaponicus,remove impurities, and dry at 60°C.
Pulverizing all the medicinal materials, sieving, and taking coarse powder (which can pass
through 24 mesh sieve, but mixed with powder which can pass through 65 mesh sieve and
not exceed 40%);
Step 2: Weigh the crude drug powder and put it into a 3000mL round bottom flask for
reflux, and add edible alcohol (60) according to the weight ratio of 1:8; Heating and refluxing for lh, collecting filtrate, and concentrating to 300ml ;;After cooling, store it in a refrigerator at 4°C for later use;
Step: Adding 8 times of water into the dregs of the step 12), heating and refluxing
twice, each time for 45 minutes; Then, the two water extracts were combined, heated and
concentrated to about 300mL, and stored in a refrigerator at 4°C after cooling.
Step 4: Take the concentrated solution in step 2 and step 3, mix them and concentrate
them to 100ml,At this time, the concentrated solution is very easy to hang on the wall, very
viscous and easy to conjunctiva on the surface;
Step 5: Take the bergamot and Panax notoginseng, remove impurities, dry and
pulverize them into coarse powder (all of which can pass through the 24 mesh sieve, but
mixed with powder which can pass through the 65 mesh sieve with no more than 40%);
Weighing bergamot, Panax notoginseng coarse powder and wall-broken Ganoderma
lucidum spore powder according to the formula amount;
Step 6. Mixing the concentrated solution in step 4 with the powder in step 5, and
continuously stirring to make it uniform. Drying in a constant temperature box at 60°C for
8h, taking out the dried product, pulverizing into coarse powder, and bagging.
Example 2
A preparation method of Polygonatum sibiricum teabag combined with exercise
prevention and auxiliary treatment of hyperglycemia comprises the following components
in parts by mass: prepared Polygonatum sibiricum 25 parts, Ophiopogon japonicus 20
parts, Dendrobium nobile 10 parts, Codonopsispilosula 20 parts, bergamot 20 parts, litchi
seeds 20 parts, Ganoderma lucidum spore powder 10 parts, lophatherum gracile 20 parts,
Alisma orientale 10 parts, Panax notoginseng 20 parts, Puerarialobata 25 parts and Grey
Paphiopedilum35 parts.
The Polygonatum sibiricum tea bag combined with exercise prevention and auxiliary
treatment of hyperglycemia is developed by the following method:
1. Pretreating raw materials: removing impurities from weighed litchi seeds,
Dendrobium, Codonopsis pilosula, Pueraria lobata, Polygonatum sibiricum, Grey
Paphiopedilum, lophatherum gracile, Alisma orientale, Ophiopogonjaponicus,bergamot
and Panax notoginseng, and drying at 50°C; Pulverizing all medicinal materials, sieving,
and taking coarse powder (the coarse powder can pass through 24 mesh sieve, and the mass
of the powder passing through 65 mesh sieve does not exceed 40% of the total coarse
powder mass);
Step 2: Weighing according to the formula;
Step 3: Develop concentrated solution:
Step 3.1: Mix the weighed litchi seeds, Dendrobium, Codonopsispilosula, Pueraria
lobata, Rhizoma PolygonatiPreparata,Grey PaphiopedilumLophatherum gracile, Alisma
orientalis and Ophiopogon japonicus coarse powder, and add 65% edible alcohol
according to the weight ratio of 1:6; Heating and refluxing for 0.5h, collecting filtrate, and
concentrating; After cooling, store it in a refrigerator at 4°C for later use;
Step 3.2: Add 8 times of water to the residue in step 3.1, and heat and reflux twice,
each time for 30min; Then combining the two water extracts, heating and concentrating,
and the volume after concentration is the same as that in step 2; After cooling, store it in a
refrigerator at 4°C for later use;
Step 3.3. Mixing the concentrated solutions developed in step 3.1 and step 3.2, and
then concentrating, wherein the volume after concentration is one third of that in step 2; At
this time, the concentrated solution is easy to hang on the wall, very viscous, and the surface
is easy to conjunctiva;
Step 4, mixing the weighed bergamot, pseudo-ginseng coarse powder and ganoderma
lucidum spore powder with the concentrated solution developed in step 3, and continuously
stirring to make them uniform; Dry in an incubator at 50°C for 10h, take out the dried
product, pulverize it into coarse powder, and bag it.
Example 3
A preparation method of Polygonatum sibiricum teabag combined with exercise
prevention and auxiliary treatment of hyperglycemia comprises the following components
in parts by mass: prepared Polygonatum sibiricum 35 parts, Ophiopogon japonicus 10
parts, Dendrobium nobile 20 parts, Codonopsispilosula 10 parts, bergamot 40 parts, litchi
seeds 10 parts, Ganoderma lucidum spore powder 20 parts, lophatherum gracile 10 parts,
Alisma orientalis20 parts, Panax notoginseng 10 parts, Puerarialobata 35 parts and Grey
Paphiopedilum25 parts.
The Polygonatum sibiricum tea bag combined with exercise prevention and auxiliary
treatment of hyperglycemia is developed by the following method:
1. Pretreating raw materials: removing impurities from weighed litchi seeds,
Dendrobium, Codonopsis pilosula, Puerarialobata, Polygonatum sibiricum, Ledouba,
lophatherum gracile, Alisma orientale, Ophiopogon japonicus, bergamot and Panax
notoginseng, and drying at 60°C; Pulverizing all medicinal materials, sieving, and taking
coarse powder (the coarse powder can pass through 24 mesh sieve, and the mass of the powder passing through 65 mesh sieve does not exceed 40% of the total coarse powder mass);
Step 2: Weighing according to the formula;
Step 3: Develop concentrated solution:
Step 3.1: Mix the weighed litchi seeds, Dendrobium, Codonopsispilosula, Pueraria
lobata, Rhizoma Polygonati Preparata, Grey Paphiopedilum, Lophatherum gracile,
Alisma orientalisand Ophiopogonjaponicuscoarse powder, and add 62% edible alcohol
according to the weight ratio of 1:8; Heating and refluxing for 1.5h, collecting filtrate, and
concentrating; After cooling, store it in a refrigerator at 4°C for later use;
Step 3.2: Add 8 times of water to the residue in step 3.1, and heat and reflux twice,
each time for 60min ; ; Then combining the two water extracts, heating and concentrating,
and the volume after concentration is the same as that in step 2; After cooling, store it in a
refrigerator at 4°C for later use;
Step 3.3, mixing the concentrated solutions developed in step 3.1 and step 3.2, and
then concentrating, wherein the volume after concentration is one third of that in step 2; At
this time, the concentrated solution is easy to hang on the wall, very viscous, and the surface
is easy to conjunctiva;
Step 4: Mixing the weighed bergamot, pseudo-ginseng coarse powder and ganoderma
lucidum spore powder with the concentrated solution developed in step 3, and continuously
stirring to make them uniform; Drying in a constant temperature box at 60°C for 8-10 hours,
taking out the dried product, crushing into coarse powder, and bagging.
The following describes the technical effects of the present invention in combination
with the specific experimental process:
1,The yield of Polygonatum sibiricum teabag for preventing and treating
hyperglycemia developed by this invention is shown in Table 1:
Table 1 Tea bag yield
Formula Coarse powder Reduced Yield% quantity /g amount /g quantity
258.88 62.23 24.04 4.16
Second, the quality inspection methods and results of teabags:
According to the weight loss, calculate the water content (%) in the test sample. Unless
otherwise specified, it shall not exceed 12.0%.
According to the method experiment, the average water content of the sample is
calculated to be 8.52%. Not exceeding the specified water content of 12.0%. Meet the
requirements of pharmacopoeia.
2,Take 10 bags of test products for the difference of loading quantity, and weigh the
contents of each bag respectively,Compared with the marked loading quantity, according
to the provisions of Pharmacopoeia, no more than 2 bags shall exceed the limit of loading
quantity difference, and no one bag shall exceed the limit by 1 time. The loading difference
shall not exceed 12%. See table 2 for the difference of loading weight.
Table 2 Test results of loading difference
number Loading Difference /g Difference
capacity /g rate/%
1 3.014 0.014 0.47
2 3.058 0.058 1.93
3 3.088 0.088 2.93
4 3.006 0.006 0.20
5 2.956 0.044 -1.47
6 2.970 0.030 -1.00
7 2.978 0.022 -0.73
8 3.026 0.026 0.87
9 2.999 0.001 -0.03
10 3.031 0.031 1.03
According to the results in Table 2, the difference in the amount of teabags is between
0.03% ~ 2.93%, not exceeding 12%, which meets the requirements of Pharmacopoeia.
Third, the inhibition experiment of tea bag on a -glucosidase
1. Test solution configuration
1.1 Preparation of PHosphate buffer: weigh 4.559g of potassium dihydrogen
phosphate and 7.646g of dipotassium hydrogen phosphate, put them into a 1000mL beaker,
add a certain amount of distilled water to stir the solution, and then adjust the ph to 6.8 in
a 500mL volumetric flask.
1.2 Preparation of a-glucosidase solution: weigh 0.03g of a-glucosidase, dissolve it in
phosphate buffer solution, and fix it in a lOmL volumetric flask with a concentration of
0.1U/mL;
1.3 Preparation of pnpg solution: weigh 0.0212PNPG, dissolve it with phosphate
buffer solution, and keep it constant in a 1OmL volumetric flask with a concentration of 1
mol/l;
1.4 Preparation of Na2CO3 solution: 0.53g anhydrous Na2CO3 is weighed and
dissolved in phosphate buffer solution, and the concentration is 1mol/1 in a 1OmL
volumetric flask;
2. Preparation of sample solution
2.1 Teabag solution: take a bag of teabags, add at least 60mL of boiling water, soak
for 15min, take the liquid, and concentrate to 60mL with a concentration of
50.00mg/mL ; ;
2.2 Preparation of positive reference substance Yuquan pill solution: take 6 Yuquan
pills, add boiling water about 30mL, soak them for 15min, the concentration is
50.00mg/mL, and take 1OmL after centrifugation for later use;
Preparation of standard curve of 3 products
In this experiment, 96-well plate was used as reaction carrier, PNPG was used as
substrate, and PNP was produced by reaction under the action of a-glucosidase. The
product has a maximum absorption peak at 405nm. By changing the amount of a
glucosidase in the system, the change of the amount of reaction products was observed,
and the most suitable reaction range was determined.
The amount of enzyme added was 4 L, 6 L, 8 L, 10tL and 12L respectively, and
the corresponding amount of substrate PNPG added was 36tL, 34tL, 32L, 30tL and 28
[1. Add a corresponding amount of a -glucosidase into each well, then add 40tL phosphate
buffer solution, and add a corresponding amount of PNPG after shaking evenly. Close the
lid, incubate at 37°C for 30 min, take it out and add 80tL Na2CO3 solution to stop the
reaction. Finally, the absorbance was detected by microplate reader, and the results were
recorded.
The absorbance test results of standard curve are shown in Table 3 .
Table 3 absorbance test results of standard curve
Enzyme four six eight 10 12 amount added L
Absorbance 0.282 0.330 0.353 0.407 0.433 value
The curve drawn according to Table 3 is shown in Figure 1,It can be seen from Figure
1 that with the increase of a -glucosidase added in the reaction system, the reaction product
increases linearly. The curve equation is: y=0.019x+0.2094, r value is 0.993, and the linear
relationship is good.
Determination of a -glucosidase inhibition rate of 4 samples
4.1 Diluted sample and reference solution: Take 16 small test tubes, which are divided
into two groups and numbered respectively. Use pipette to take 2mL of teabag sample
solution into the first test tube, and the concentration is 0.05g/mL. Use another pipette to
take 1mL of the solution in the first test tube and add 1mL of distilled water to the second
test tube. Then take 1mL of solution from the second test tube to the third test tube, and
make up 1mL of distilled water. Dilute to the eighth test tube in turn, and the dilution
multiples of the eight test tubes are 16, 32 and 64 respectively. The positive reference
solution was diluted by the same method for later use.
4.2 Reaction system: a enzyme 4[L+PNPG36[tL+ teabag sample solution 40L/
Yuquan pill solution 40 L/phosphate buffer solution 40[IL+Na2CO3 solution 80 L 1.
4.3 Reaction and determination
Sample group, positive control group and blank group all reacted with 160ul reaction
system, which was: a -glucosidase 4 L+PNPG36 l+40 L sample/positive
control/phosphate buffer +80jL Na2CO3. Add 4 [t1 a -glucosidase and 40 L
inhibitor/phosphate buffer solution into each reaction well, and mix them evenly on the
shaker. Then, 36 1 ofNPG was added, covered, and incubated at 37°C for 30min. Take it
out and add 80 L Na2CO3 solution to stop the reaction. In addition, the blank control of
each group should be added with 40 L inhibitor of equal concentration and supplemented
with 120 L phosphate buffer. Finally, the absorbance was measured by microplate reader,
and the results were recorded.
Considering the influence of the color of samples, the two groups with the highest
concentration of each inhibitory solution were discarded,The sample group was divided into three groups with dilution ratios of 16, 32 and 64, and the positive control group was divided into three groups with dilution ratios of 16, 32 and 64 respectively. The blank group was phosphate buffer solution, which was repeated three times to get the average value. Each group was set with the control of corresponding concentration. See table 4 for specific concentration gradient design.
Table 4 Concentration Table of Samples and Positive Reference Substances in
Reaction System
number Sample group Positive group Blank group (teabag) (Yuquan Pill)
Mg/mL mg/mL
1 16 times, 3.13 16 times, 3.13 Phosphate 2 32 times, 1.56 32 times, 1.56 buffered saline solution 3 64 times, 0.78 64 times, 0.78
4.4 If the absorbance measured by the sample group is Al, the sample control is Al',
and the absorbance of the blank control group is AO, then the calculation (formula) of the
inhibition rate of the sample at this time is:
[AO - (A1 - A1')] Sample inhibition rate = AO x 100%
The inhibition rate of positive reference substance can be calculated by the same
method.
4.5 Detection results of inhibition rate of a -glucosidase by samples: The detection
results are shown in Table 5 .
Table 5 Detection results of inhibition rate of a -glucosidase by samples (n=3)
Sample Blank Blank Concentration _ Inhibition A RSD% control of AA control (mg/mL) samples (AO) rate (%)
Teabag 3.13 0.318 0.065 0.255 0.163 83.24*
1.56 0.306 0.012 0.215 0.191 75.79
0.78 0.281 0.046 0.166 0.215 69.41 0.376 Yuquanwan 3.13 0.430 0.034 0.285 0.246 61.43
1.56 0.329 0.030 0.225 0.204 72.34*
0.78 0.318 0.025 0.187 0.231 65.15
Table 5 shows that the diluted solution of teabag and Yuquan Pill can inhibit the
activity of a-glucosidase, and the highest inhibition rate is 83.24% when the concentration
of teabag is 3.13mg/mL; When the concentration of Yuquan Pill was 1.56mg/mL, the
highest inhibition rate was 72.34%,The inhibitory effect of teabag was better than that of
Yuquan Pill. Spss software was used to analyze the difference of data, P<0.05, which
showed that there was significant difference between the two highest inhibition rates when
grouping was used as variable.
Fourth, the hypoglycemic effect of teabags in vivo
1. Preparation of sample solution: Take a bag of teabags, add 60mL boiling water, and
extract with ultrasonic for 15min, twice. Take the liquid and concentrate it to 1OmL with a
concentration of 300mg/mL, which is a high concentration sample solution; Dilute the
high-concentration sample solution to obtain medium and low-concentration sample
solutions with the concentrations of 30mg/mL and 3mg/mL, respectively.
2. Experimental methods
2.1 establishment and grouping of animal models
The mice were fasted without water for 12 hours. Except the blank group, 80 mg/kg
alloxan was injected into the tail vein of other groups, and after 72 hours of normal feeding,
the mice were fasted for 12 hours without water retention,Three mice were randomly taken
to take blood from their eyes to measure fasting blood glucose, and the blood glucose value was greater than 11.1 mmol/L, indicating that the model was successful. The successful mice were randomly divided into three groups: administration group (3 groups), model group and positive control group (acarbose). Normal mice were the blank group. 10 mice in each group, half male and half female. See table 6 for the administration of each group.
The experimental groups were administered once a day from 8: 00 am to 8: 30 am for 7
days.
Table 6 Animal grouping and drug concentration table
Gastric perfusion Group Dosage volume
High dose group Teabag 4g/kg 0.4ml
Medium dose group Tea bag 0.4 g/kg 0.4ml
Low-dose group Tea bag 0.04g/kg 0.4ml
Positive control group Acarbose 75mg/kg 0.4ml
Model group physiological saline 0.4ml
Blank group physiological saline 0.4ml
2.2 Index determination
Two hours after the last administration, blood was collected from the orbit, serum was
separated, and the postprandial blood glucose of mice was measured,After fasting for 12
hours that night, eyeball blood was collected to measure the fasting blood glucose and
insulin content of mice.
2.3 Data processing
The insulin content was calculated by Elisa Calc regression/fitting calculation
program, and the others were calculated and analyzed by spss.
3. Result analysis
3.1 Effect of teabags on postprandial blood glucose in diabetic mice
The measurement results of postprandial blood glucose of diabetic mice in each group
are shown in Table 7.
Table 7 Determination results of postprandial blood glucose of diabetic mice in each
group
Average postprandial Group Dosage blood glucose (mmol/L)
High dose group Teabag 4g/kg 28.1 'c
Medium dose group Tea bag 0.4 g/kg 28.3 'c
Low-dose group Tea bag 0.04g/kg 29.2 bd
Positive control group Acarbose 75mg/kg 27.3 bcd
Model group physiological saline 34.1 acd
Blank group physiological saline 5. 1bcd
It can be seen from the results in Table 7 that the postprandial blood glucose level of
the blank group is significantly lower than that of other groups, which proves the success
of modeling. The postprandial blood glucose values of the positive control group and the
administration group were significantly lower than those of the model group, which proved
that acarbose and teabags had significant effects on reducing postprandial blood
glucose,There was no significant difference between the high and medium dose
administration groups and the positive control group, but the hypoglycemic effect of the
low dose group was significantly lower than that of the positive control group. The
experimental results show that teabags can reduce postprandial blood sugar.
3.2 Effect of Tea Bag on Fasting Blood Glucose in Diabetic Mice
Table 8 Fasting blood glucose measurement results of diabetic mice in each group
Average fasting blood Group Dosage glucose (mmolL)
High dose group Teabag 4g/kg 18.1 'c
Medium dose group Tea bag 0.4 g/kg 18.7 'c
Low-dose group Tea bag 0.04g/kg 19.7 bd
Positive control group Acarbose 75mg/kg 18.5 'c
Model group Physiological saline 23.2 acd
Blank group Physiological saline 4 .8bcd
The measurement results of fasting blood glucose of diabetic mice in each group are
shown in table 8; It can be seen from Table 8 that the fasting blood glucose in the blank
group was significantly lower than that in other groups, and the model was successfully
established. Positive control acarbose and teabags of different doses can significantly
reduce fasting blood glucose, and their fasting blood glucose values are significantly
different from those of the model group. Among them, there was no significant difference
in fasting blood glucose between the high-dose and medium-dose teabags and the positive
control group, which indicated that there was no significant difference in hypoglycemic
effect,The fasting blood glucose value of the low-dose teabags was significantly higher
than that of the model group, which showed that the low-dose teabags had the effect of
lowering fasting blood glucose, but the effect was not as strong as acarbose.
3.3 Effect of Tea Bag on Insulin Content in Diabetic Mice
The determination results of insulin content in diabetic mice in each group are shown
in Table 9.
Table 9 Determination results of insulin content in diabetic mice of each group
Group Dosage Insulin (ngmL)
High dose group Teabag 4g/kg 17.3 b
Medium dose group Tea bag 0.4 g/kg 16.9b
Low-dose group Tea bag 0.04g/kg 16.0 b
Positive control group Acarbose 75mg/kg 16.7b
Model group physiological saline 10.5 'c
Blank group physiological saline 26.la
It can be seen from Table 9 that the insulin content in the blank group is obviously
higher than that in other groups, which shows that the model was successfully established.
Both positive control group and bagged tea can significantly increase insulin content, and
there is no significant difference among the groups. The results showed that high, medium
and low dose tea bags and positive control group had a considerable effect on increasing
insulin content in diabetic mice.
To sum up, tea bags can reduce blood sugar by the following ways: (1) inhibiting a
glucosidase and (2) promoting insulin secretion by islet cells.
The above description shows and describes several preferred embodiments of the
invention, but as mentioned above, it should be understood that the invention is not limited
to the form disclosed herein, and should not be regarded as excluding other embodiments,
but can be used in various other combinations, modifications and environments, and can
be changed within the scope of the inventive concept described herein by the above
teaching or the technology or knowledge in relevant fields. However, the modifications
and changes made by those skilled in the art do not depart from the spirit and scope of the
invention, and should be within the protection scope of the appended claims.
Claims (6)
1. A preparation method of Polygonatum sibiricum tea bag combined with exercise
for prevention and adjuvant therapy for hyperglycemia, which is characterized in that it
comprises the following components in parts by mass: prepared Polygonatum sibiricum
-35 parts, Ophiopogon japonicus 10-20 parts, Dendrobium nobile 10-20 parts,
Codonopsispilosula 10-20 parts, Citrus medica sarcodactylis20-40 parts, Litchi chinensis
seeds 10-20 parts, Ganodermalucidum spore powder 10-20 parts, lophatherumgracile 10
parts, Alisma orientale 10-20 parts, Panax ginseng 10-20 parts, Puerarialobata 25-35
parts, 25-35 parts of Grey Paphiopedilum;
2. The preparation method of Polygonatum sibiricum tea bag combined with exercise
for prevention and adjuvant therapy for hyperglycemia is characterized in that it comprises
the following steps:
Step 1: Pre-treatment of raw materials: Weigh the Litchi chinensis seeds, Codonopsis
pilosula, Pueraria lobata, Polygonatum sibiricum, Grey Paphiopedilum, lophatherum
gracile, Alisma orientale, Ophiopogonjaponicus,Citrus medica sarcodactylisand Panax
ginseng and dry them; crush all the herbs, which are passed through a sieve and take the
coarse powder.
Step 2: Weighing: Weighing the pre-treated coarse powder according to the mass
parts: prepared Polygonatum sibiricum 25-35 parts, Ophiopogonjaponicus 10-20 parts,
Dendrobium nobile 10-20 parts, Codonopsis pilosula 10-20 parts, Citrus medica
sarcodactylis 20-40 parts, Litchi chinensis seeds 10-20 parts, Ganoderma lucidum spore
powder 10-20 parts, lophatherumgracile 10-20 parts, Alisma orientale 10-20 parts, Panax
ginseng 10-20 parts, Puerarialobata 25-35 parts, 25-35 parts of Grey Paphiopedilum.
Step 3: Prepare the concentrated liquid.
Step 4: Mix the weighed Citrus medica sarcodactylis, Panaxginseng coarse powder
and Ganoderma lucidum spore powder with the concentrated liquid prepared in Step 3,
stirring it continuously to make it uniform; dry it in a constant temperature oven, take out
the dried product, crush it into coarse powder, bag it, and obtain the Polygonatum sibiricum
tea bag for prevention and adjuvant therapy for hyperglycemia.
3. The preparation method of Polygonatum sibiricum tea bag combined with exercise
for prevention and adjuvant therapy for hyperglycemia according to claim 2 is
characterized in that the coarse powder in step 1 can pass through a 24 mesh sieve, and the
mass of the powder passing through a 65 mesh sieve does not exceed 40% of the total
coarse powder mass.
4. The preparation method of Polygonatum sibiricum tea bag combined with exercise
for prevention and adjuvant therapy for hyperglycemia according to claim 2 is
characterized in that the drying temperature in step 1 is 50°C-60°C.
5. The preparation method of Polygonatum sibiricum tea bag combined with exercise
for prevention and adjuvant therapy for hyperglycemia according to claim 2 is
characterized in that the concentrate solution prepareed in that step 3 specifically comprises
the following steps:
Step 3.1: Mix the weighed LLitchi chinensis seeds, Codonopsis pilosula, Pueraria
lobata, Polygonatum sibiricum, Grey Paphiopedilum, lophatherum gracile, Alisma
orientale, Ophiopogonjaponicus,Citrus medica sarcodactylis and Panaxginseng, add 60
degrees-65 degrees edible alcohol according to the weight ratio of 1:6-1:8; heat reflux for
0.5h-1.5h, take the filtrate, concentrate; cool and store in 4°C refrigerator, set aside; then combine the two aqueous extracts in step 3.1, heat reflux for 30-60min each time; then combine the two aqueous extracts, concentrate the volume with that of step 2.
Step 3.2: Take the dregs from step 3.1, add 8 times the amount of water, heat and
reflux twice, 30-60min each time; then combine the two water extracts, heat and
concentrate, the volume after concentration is the same as in step 2; cool and store in a
refrigerator at 4°C, and set aside.
Step 3.3. Take the concentrated solution prepareed in step 3.1 and step 3.2 and mix,
then concentrate, and the volume after concentration is one third of that in step 2; prepare
the concentrated solution and set aside.
6. The preparement method of Polygonatum sibiricum tea bag for preventing and
adjuvant treating hyperglycemia according to claim 2, characterized in that the drying
temperature in step 4 is 50°C-60°C; Drying time is 8h-10h.
FIGURES 1/1
Figure 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021101743A AU2021101743A4 (en) | 2021-04-06 | 2021-04-06 | Preparation Method of Polygonatum sibiricum Tea Bag Combined with Exercise for Prevention and Adjuvant Therapy for Hyperglycemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021101743A AU2021101743A4 (en) | 2021-04-06 | 2021-04-06 | Preparation Method of Polygonatum sibiricum Tea Bag Combined with Exercise for Prevention and Adjuvant Therapy for Hyperglycemia |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021101743A4 true AU2021101743A4 (en) | 2021-05-27 |
Family
ID=76094328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021101743A Ceased AU2021101743A4 (en) | 2021-04-06 | 2021-04-06 | Preparation Method of Polygonatum sibiricum Tea Bag Combined with Exercise for Prevention and Adjuvant Therapy for Hyperglycemia |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2021101743A4 (en) |
-
2021
- 2021-04-06 AU AU2021101743A patent/AU2021101743A4/en not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102697047B (en) | Method for preparing oral liquid of Chinese wolfberry | |
CN101595988B (en) | Health-care food preparation for alleviating fatigue and preparation method thereof | |
CN101053621B (en) | Traditional Chinese medicinal composition for treating obesity and its preparation method | |
CN101982193B (en) | Traditional Chinese medicine composition for treating pulmonary tuberculosis, preparation method and application thereof | |
CN102271698A (en) | Pharmaceutical composition and use for preparing medicament thereof | |
CN101390887A (en) | Medicine composition of Panax notoginseng saponins | |
CN108713746A (en) | A kind of integration of drinking and medicinal herbs composition and its preparation method and application | |
CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
CN102048902B (en) | Hepatitis treating traditional Chinese medicine composition, extract and preparation method, application and formulation | |
CN1330345C (en) | Combination of Chinese traditional medicine for treating hyperlipemia, and preparation method | |
CN106822583A (en) | A kind of regulation blood pressure, blood fat, Chinese medicine composition of blood sugar and preparation method thereof | |
CN104225295B (en) | Composition for improving sleep, and preparation method and application thereof | |
CN114848727B (en) | Preparation method and application of American ginseng paste | |
AU2021101743A4 (en) | Preparation Method of Polygonatum sibiricum Tea Bag Combined with Exercise for Prevention and Adjuvant Therapy for Hyperglycemia | |
CN103446266A (en) | Traditional Chinese medicinal compound preparation for treating type 2 diabetes, and preparation method thereof | |
CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
CN102134550A (en) | Health-care tonic wine and preparation process thereof | |
CN106214787B (en) | A kind of Chinese medicine composition for treating diabetes and preparation method thereof and purposes | |
CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
CN113599447A (en) | Traditional Chinese medicine composition for improving phlegm-dampness constitution and preparation method and application thereof | |
CN101293059B (en) | Compound Chinese medicine for treating diabetes | |
CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
CN110279804A (en) | A kind of antifatigue rhizoma polygonati Chinese medicine composition and its health liquor | |
CN106822632B (en) | Polygonatum sibiricum tea bag for preventing and assisting in treating diabetes and preparation method thereof | |
CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |